Tyler Gorman, PA; James Alstott, MD
WMJ. 2026;125(4):533-536. Published November 1, 2026.
ABSTRACT
Introduction: Rosuvastatin is a widely prescribed, high-potency statin for cardiovascular risk reduction. Rare cases of nephrotoxicity have been reported, particularly in patients with reduced kidney function.
Case Presentation: We present a case of a 57-year-old Black man who developed proteinuria and declining renal function following initiation of high-dose rosuvastatin (40 mg daily) after an acute coronary event. After other causes were excluded, the rosuvastatin was gradually reduced to 10 mg, resulting in improvement of renal function and resolution of proteinuria.
Discussion: Prior reports have linked rosuvastatin to acute interstitial nephritis and tubular injury, with recovery following drug discontinuation. This case is notable because the patient’s baseline creatinine level was normal prior to rosuvastatin initiation, and recovery occurred with dose reduction rather than complete drug cessation.
Conclusions: Clinicians should consider rosuvastatin-associated nephrotoxicity in patients with unexplained renal dysfunction or proteinuria. Early recognition and dose reduction or drug discontinuation may prevent long-term renal sequelae while maintaining adequate lipid control.